Alliqua (ALQA) Reports Prelim. Q1 Revenue of $4.6M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cowen Resumes Alliqua, Inc (ALQA) at Outperform; Sees 200%+ Upside
April 10, 2017 6:26 AM EDTCowen resumes coverage on Alliqua, Inc (NASDAQ: ALQA) with a Outperform rating and a price target of $1.50.
Analyst Joshua Jennings highlights the company recently posted Q1 revenue growth of 28% year-over-year, driven by its Biologics franchise growth of ~200%.
The analyst said Biovance, Interfyl,... More
